• More amenable to use in children and the elderly
  • Cross protective, valuable for seasonal changes in influenza and valuable for pandemics
  • More effective vaccines, for example for TB
  • More boostable immune responses
  • Lower dose is required, reducing costs and time of manufacture, and facilitating storage and logistics issues etc.
  • No lag time to bank feedstocks & manufacture vaccine lots